Amylin Pharmaceuticals
 |
|
| Private | |
| Traded as | AMLN |
| Industry | Biotechnology |
| Founded | 1987 |
| Headquarters | San Diego, California, United States |
|
Key people
|
Daniel M. Bradbury |
| Products | Symlin (pramlintide) Byetta (exenatide) Bydureon (exenatide long-acting release) |
| Revenue |
 US$758M (FY 2009)
|
 US$-173M (FY 2009)
|
|
|
US$-186M (FY 2009)
|
|
| Total assets |
US$1.73B (FY 2009)
|
| Total equity |
US$423M (FY 2009)
|
|
Number of employees
|
1,900 [1] |
| Website | www.amylin.com |
Amylin Pharmaceuticals was a biopharmaceutical company based in San Diego, CA, that was founded in 1987. The company was engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases. Amylin produced three drugs: Symlin (pramlintide acetate), Byetta (exenatide) and Bydureon (exenatide extended-release).
In July 2012, Bristol-Myers Squibb announced it would acquire Amylin Pharmaceuticals for $5.3 billion. As part of the acquisition, AstraZeneca made a $3.4 billion cash payment to make Amylin a wholly owned subsidary within the existing BMS/AZ joint venture in diabetes. In April 2013, Bristol-Myers Squibb announced it would close Amylin's San Diego operations by the end of 2014 and merge the Amylin manufacutring facility in West Chester, Ohio and all field-based sales personnel into Bristol-Myers Squibb operations.
In December 2013, AstraZeneca purchased the Bristol-Myers Squibb share of the diabetes joint venture, and as a result, became the sole owner of all former Amylin products and business, including the manufacturing facility in West Chester, Ohio.
On February 4, 2014, the U.S. FDA approved Myalept (metreleptin), an analog of human leptin, as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital generalized or acquired generalized lipodystrophy. Metraleptin was originally developed at Amylin Pharmaceuticals. In November 2014, Aegerion Pharmaceuticals made a $325 million cash payment to AstraZeneca to acquire and commercialize metreleptin.
...
Wikipedia